Graticule Asia Macro Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Graticule Asia Macro Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-18,018	Closed	-$923K	–	113
2017 Q1	$923K	Buy	+18,018	New	+$833K	0.05%	109
2016 Q1	–	Sell	-21,437	Closed	-$2.02M	–	86
2015 Q4	$2.02M	Buy	21,437 +9,437	+79%	+$875K	0.33%	50
2015 Q3	$964K	Buy	+12,000	New	+$1.33M	0.11%	69

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Graticule Asia Macro Advisors's ALNY Position: Q2 2017 in Review

Graticule Asia Macro Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2017, closing a stake of 18,018 shares — an estimated $923K sold.

Graticule Asia Macro Advisors first reported a position in ALNY in Q3 2015 and held it in 3 quarters. The position peaked at $2.02M in Q4 2015. 227 funds tracked by Wall St. Rank hold ALNY as of Q2 2017.

Graticule Asia Macro Advisors reported no remaining Alnylam Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
Graticule Asia Macro Advisors sold 18,018 Alnylam Pharmaceuticals shares in Q2 2017, an estimated $923K.
Graticule Asia Macro Advisors first reported a position in Alnylam Pharmaceuticals in Q3 2015 and held it in 3 quarters.
Graticule Asia Macro Advisors's Alnylam Pharmaceuticals position peaked at $2.02M in Q4 2015.
227 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2017.

Based on Graticule Asia Macro Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.